Vertex Pharmaceuticals (VRTX) Non-Current Assets (2009 - 2026)

Vertex Pharmaceuticals has reported Non-Current Assets for 18 years, with the latest figure at $14.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 14.62% year-over-year to $14.8 billion; the trailing twelve-month figure through Mar 2026 stood at $57.1 billion (up 15.5% YoY), and the FY2025 full-year result was $14.4 billion, up 11.64% from the prior year.
• Non-Current Assets for Q1 2026 stood at $14.8 billion, up from $14.4 billion in the prior quarter.
• The five-year high for Non-Current Assets was $14.8 billion in Q1 2026, with the low at $3.9 billion in Q1 2022.
• Average Non-Current Assets over 5 years is $9.6 billion, with a median of $10.6 billion recorded in 2024.
• Year-over-year, Non-Current Assets rose 8.36% in 2022 and soared 76.89% in 2024.
• Tracing VRTX's Non-Current Assets over 5 years: stood at $4.9 billion in 2022, then surged by 74.65% to $8.6 billion in 2023, then jumped by 50.67% to $12.9 billion in 2024, then increased by 11.64% to $14.4 billion in 2025, then grew by 2.16% to $14.8 billion in 2026.
• The last three Non-Current Assets figures came in at $14.8 billion (Q1 2026), $14.4 billion (Q4 2025), and $14.3 billion (Q3 2025), per Business Quant data.

Peer Comparison